CN1213064C - 序列号28的生物活性肽 - Google Patents
序列号28的生物活性肽 Download PDFInfo
- Publication number
- CN1213064C CN1213064C CNB021410429A CN02141042A CN1213064C CN 1213064 C CN1213064 C CN 1213064C CN B021410429 A CNB021410429 A CN B021410429A CN 02141042 A CN02141042 A CN 02141042A CN 1213064 C CN1213064 C CN 1213064C
- Authority
- CN
- China
- Prior art keywords
- peptide
- group
- physiological saline
- compare
- significant difference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 398
- 230000000975 bioactive effect Effects 0.000 title abstract description 11
- 239000002773 nucleotide Substances 0.000 claims abstract description 25
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims description 63
- 239000003814 drug Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 29
- 244000005700 microbiome Species 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 15
- 230000002068 genetic effect Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000002504 physiological saline solution Substances 0.000 description 171
- 102000000588 Interleukin-2 Human genes 0.000 description 106
- 108010002350 Interleukin-2 Proteins 0.000 description 106
- 102100037850 Interferon gamma Human genes 0.000 description 76
- 108010074328 Interferon-gamma Proteins 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 74
- 108010034465 CMS 024 Proteins 0.000 description 61
- 125000003275 alpha amino acid group Chemical group 0.000 description 60
- 241001465754 Metazoa Species 0.000 description 55
- 241000699666 Mus <mouse, genus> Species 0.000 description 54
- 230000000694 effects Effects 0.000 description 52
- 238000011282 treatment Methods 0.000 description 51
- 108010085335 Pro-Thr-Thr-Lys-Thr-Tyr-Phe-Pro-His-Phe Proteins 0.000 description 50
- 241000700159 Rattus Species 0.000 description 50
- 102000004196 processed proteins & peptides Human genes 0.000 description 46
- 238000012453 sprague-dawley rat model Methods 0.000 description 42
- 230000037396 body weight Effects 0.000 description 40
- 210000002966 serum Anatomy 0.000 description 40
- 241000894006 Bacteria Species 0.000 description 36
- 239000013604 expression vector Substances 0.000 description 34
- 241000282898 Sus scrofa Species 0.000 description 30
- 210000000952 spleen Anatomy 0.000 description 30
- 238000002347 injection Methods 0.000 description 28
- 239000007924 injection Substances 0.000 description 28
- 230000004083 survival effect Effects 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 24
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 239000006228 supernatant Substances 0.000 description 23
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 22
- 238000010790 dilution Methods 0.000 description 21
- 239000012895 dilution Substances 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 201000007270 liver cancer Diseases 0.000 description 20
- 208000014018 liver neoplasm Diseases 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 230000036541 health Effects 0.000 description 18
- 208000002672 hepatitis B Diseases 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 230000000242 pagocytic effect Effects 0.000 description 18
- 239000000902 placebo Substances 0.000 description 18
- 229940068196 placebo Drugs 0.000 description 18
- 210000004988 splenocyte Anatomy 0.000 description 18
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 17
- 206010039491 Sarcoma Diseases 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000000822 natural killer cell Anatomy 0.000 description 16
- 238000011160 research Methods 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 239000012980 RPMI-1640 medium Substances 0.000 description 15
- 208000032839 leukemia Diseases 0.000 description 15
- 230000000527 lymphocytic effect Effects 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000009385 viral infection Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000001079 digestive effect Effects 0.000 description 13
- 201000001441 melanoma Diseases 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 230000003187 abdominal effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 239000002547 new drug Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000011725 BALB/c mouse Methods 0.000 description 11
- 230000005907 cancer growth Effects 0.000 description 11
- 239000006285 cell suspension Substances 0.000 description 11
- 229940109239 creatinine Drugs 0.000 description 11
- 230000001472 cytotoxic effect Effects 0.000 description 11
- 238000001647 drug administration Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000272525 Anas platyrhynchos Species 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 206010018364 Glomerulonephritis Diseases 0.000 description 9
- 239000006143 cell culture medium Substances 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 244000309466 calf Species 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- APHGWLWMOXGZRL-DCAQKATOSA-N Glu-Glu-His Chemical compound N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O APHGWLWMOXGZRL-DCAQKATOSA-N 0.000 description 7
- 241001494479 Pecora Species 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 7
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 108010085325 histidylproline Proteins 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 6
- 108010062580 Concanavalin A Proteins 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 description 6
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 6
- FXVDGDZRYLFQKY-WPRPVWTQSA-N Val-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C FXVDGDZRYLFQKY-WPRPVWTQSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 6
- 108010003700 lysyl aspartic acid Proteins 0.000 description 6
- 108010005942 methionylglycine Proteins 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 108700031361 Brachyury Proteins 0.000 description 5
- 238000011765 DBA/2 mouse Methods 0.000 description 5
- 206010013183 Dislocation of vertebra Diseases 0.000 description 5
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 125000000017 cortisol group Chemical group 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 229960001627 lamivudine Drugs 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- UQULNJAARAXSPO-ZCWPNWOLSA-N Glu-Thr-Thr-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UQULNJAARAXSPO-ZCWPNWOLSA-N 0.000 description 4
- AQLHORCVPGXDJW-IUCAKERBSA-N Gly-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN AQLHORCVPGXDJW-IUCAKERBSA-N 0.000 description 4
- DENRBIYENOKSEX-PEXQALLHSA-N Gly-Ile-His Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 DENRBIYENOKSEX-PEXQALLHSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 238000001311 chemical methods and process Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108010056582 methionylglutamic acid Proteins 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 108010031719 prolyl-serine Proteins 0.000 description 4
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 235000015961 tonic Nutrition 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 235000021262 sour milk Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- 108010076441 Ala-His-His Proteins 0.000 description 2
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- NPZJLGMWMDNQDD-GHCJXIJMSA-N Asn-Ser-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NPZJLGMWMDNQDD-GHCJXIJMSA-N 0.000 description 2
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 2
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- UTKICHUQEQBDGC-ACZMJKKPSA-N Glu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UTKICHUQEQBDGC-ACZMJKKPSA-N 0.000 description 2
- BPLNJYHNAJVLRT-ACZMJKKPSA-N Glu-Ser-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O BPLNJYHNAJVLRT-ACZMJKKPSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 description 2
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- BZAQOPHNBFOOJS-DCAQKATOSA-N His-Pro-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O BZAQOPHNBFOOJS-DCAQKATOSA-N 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- LWWILHPVAKKLQS-QXEWZRGKSA-N Ile-Gly-Met Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N LWWILHPVAKKLQS-QXEWZRGKSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- QPXBPQUGXHURGP-UWVGGRQHSA-N Leu-Gly-Met Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N QPXBPQUGXHURGP-UWVGGRQHSA-N 0.000 description 2
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 2
- IRNSXVOWSXSULE-DCAQKATOSA-N Lys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN IRNSXVOWSXSULE-DCAQKATOSA-N 0.000 description 2
- HUKLXYYPZWPXCC-KZVJFYERSA-N Met-Ala-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HUKLXYYPZWPXCC-KZVJFYERSA-N 0.000 description 2
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 229940083963 Peptide antagonist Drugs 0.000 description 2
- KIAWKQJTSGRCSA-AVGNSLFASA-N Phe-Asn-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KIAWKQJTSGRCSA-AVGNSLFASA-N 0.000 description 2
- AWAYOWOUGVZXOB-BZSNNMDCSA-N Phe-Asn-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 AWAYOWOUGVZXOB-BZSNNMDCSA-N 0.000 description 2
- IDUCUXTUHHIQIP-SOUVJXGZSA-N Phe-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O IDUCUXTUHHIQIP-SOUVJXGZSA-N 0.000 description 2
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 2
- JWQWPTLEOFNCGX-AVGNSLFASA-N Phe-Glu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWQWPTLEOFNCGX-AVGNSLFASA-N 0.000 description 2
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 2
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 2
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 2
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 2
- 241000594182 Sarcophaga sigma Species 0.000 description 2
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 2
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 2
- HRHYJNLMIJWGLF-BZSNNMDCSA-N Tyr-Ser-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 HRHYJNLMIJWGLF-BZSNNMDCSA-N 0.000 description 2
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 108010079547 glutamylmethionine Proteins 0.000 description 2
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960002181 saccharomyces boulardii Drugs 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- MPLOSMWGDNJSEV-WHFBIAKZSA-N Ala-Gly-Asp Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MPLOSMWGDNJSEV-WHFBIAKZSA-N 0.000 description 1
- OCDJOVKIUJVUMO-SRVKXCTJSA-N Arg-His-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N OCDJOVKIUJVUMO-SRVKXCTJSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- ORYMMTRPKVTGSJ-XVKPBYJWSA-N Gln-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O ORYMMTRPKVTGSJ-XVKPBYJWSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- MUGLKCQHTUFLGF-WPRPVWTQSA-N Gly-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CN MUGLKCQHTUFLGF-WPRPVWTQSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- LMMBAXJRYSXCOQ-ACRUOGEOSA-N Lys-Tyr-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O LMMBAXJRYSXCOQ-ACRUOGEOSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- GOUWCZRDTWTODO-YDHLFZDLSA-N Phe-Val-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O GOUWCZRDTWTODO-YDHLFZDLSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- QBFONMUYNSNKIX-AVGNSLFASA-N Pro-Arg-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QBFONMUYNSNKIX-AVGNSLFASA-N 0.000 description 1
- XQHGISDMVBTGAL-ULQDDVLXSA-N Pro-His-Phe Chemical compound C([C@@H](C(=O)[O-])NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1[NH2+]CCC1)C1=CC=CC=C1 XQHGISDMVBTGAL-ULQDDVLXSA-N 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 241000204115 Sporolactobacillus inulinus Species 0.000 description 1
- JTMZSIRTZKLBOA-NWLDYVSISA-N Trp-Thr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O JTMZSIRTZKLBOA-NWLDYVSISA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001518 anti-nephritic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- -1 frost Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019476 oil-water mixture Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 108010089164 prolyl-leucyl-asparagyl-prolyl-lysine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
SEQ ID NO: | 肽名称 | 肽序列 |
1 | CMS001 | Pro Thr Thr Lys Tyr Phe Pro His Phe |
2 | CMS002 | Val Val Tyr Prp Trp Thr Gln Arg Phe |
3 | CMS008 | Lys Ala Val Gly His Leu Asp Asp Leu Pro Gly Ala Leu |
4 | CMS010 | Val Ala Pro Glu Glu His Pro Thr Leu Leu Thr Glu Ala ProLeu Asn Pro Lys |
5 | CMS012 | Leu Gly Met Glu Ala Cys Gly Ile His Glu Thr Thr Tyr |
6 | CMS013 | Leu Arg Val Ala Pro Glu Glu His Pro Val Leu |
7 | CMS014 | Ala Ala His His Pro Asp Asp Phe Asn Pro Ser Val |
8 | CMS015 | Pro Ser Ile Val Gly AgPro Arg His Gln Gly Val Met |
9 | CMS016 | Ile Gly Met Glu Ser Ala Gly Ile His Glu Thr Thr Tyr |
10 | CMS018 | Val Gly Met Gly Glu Lys Asp Ser Tyr |
11 | CMS019 | Val Gly Met Gly Gln Lys Asp Ser Tyr |
12 | CMS020 | Val Gly Met Gly Gln Lys Asp Ser Tyr Val |
13 | CMS021 | Met Ala Thr Ala Ala Ser Ser Ser Ser Leu |
14 | CMS022 | Tyr Ser Phe |
15 | CMS023 | Ala Ala Phe |
16 | CMS024 | Tyr Ser Leu |
17 | CMS026 | Thr Thr Tyr Asn Ser Ile Met |
18 | CMS027 | Phe Glu Glu Asn Met |
19 | CMS028 | Phe Glu Pro Ser Phe |
20 | CMS029 | Phe Asn Glu Glu |
21 | CMS030 | Phe Glu Glu Met |
22 | CMS032 | Phe Glu Glu Glu |
23 | CMS033 | Phe Glu Ser Phe |
24 | CMS034 | Pro Glu Asn Phe |
25 | CMS035 | Phe Val Asn Asp |
26 | CMS036 | Phe Gln Pro Ser Phe |
27 | CMS003 | Phe Asn Phe Val Pro Pro |
28 | CMS007 | Ala Gly Asp Asp Ala Pro Arg Ala Val Phe |
29 | CMS009 | Leu Arg Val Ala Pro Glu Glu His Pro Thr Leu |
30 | CMS011 | Arg Val Ala Pro Glu Glu His Pro Thr Leu |
阳性对照组(g) | CMS015治疗组(g) | |||
雄性n=5 | 雌性n=5 | 雄性n=5 | 雌性n=5 | |
治疗前 | 145.6±13.6 | 133.6±46 | 145.6±8.5 | 129.2±3.3 |
治疗后第1周 | 194.4±14.5 | 164.4±8.7 | 183.8±10.6 | 157.8±8.3 |
治疗后第2周 | 239.6±13.4 | 188.0±6.4 | 220.6±12.2* | 176.0±11.2* |
治疗后第3周 | 265.0±11.8 | 208.8±8.2 | 239.0±16.0* | 196.0±10.5* |
治疗后第4周 | 287.4±17.7 | 227.2±8.2 | 258.2±18.1* | 212.0±13.5* |
治疗后第5周 | 299.4±21.2 | 236.6±10.9 | 268.8±17.7* | 221.4±13.2* |
治疗后第6周 | 333.4±27.1 | 249.4±16.3 | 299.4±21.2* | 235.6±16.3 |
治疗后第7周 | 349.2±28.9 | 261.2±13.4 | 310.4±25.9* | 242.2±18.8* |
治疗后第8周 | 374.4±37.2 | 255.6±11.5 | 337.4±30.6 | 252.8±22.5 |
Claims (9)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90449201A | 2001-07-13 | 2001-07-13 | |
US09/904,492 | 2001-07-13 | ||
US17868402A | 2002-06-20 | 2002-06-20 | |
US10/178,684 | 2002-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1398892A CN1398892A (zh) | 2003-02-26 |
CN1213064C true CN1213064C (zh) | 2005-08-03 |
Family
ID=26874547
Family Applications (30)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021410402A Expired - Fee Related CN1213062C (zh) | 2001-07-13 | 2002-07-11 | 序列号13的生物活性肽 |
CN021409862A Expired - Fee Related CN1216070C (zh) | 2001-07-13 | 2002-07-11 | 序列号20的生物活性肽 |
CNB021409870A Expired - Fee Related CN1210299C (zh) | 2001-07-13 | 2002-07-11 | 序列号19的生物活性肽 |
CNB021409714A Expired - Fee Related CN1210296C (zh) | 2001-07-13 | 2002-07-11 | 序列号30的生物活性肽 |
CNB021410372A Expired - Fee Related CN1210301C (zh) | 2001-07-13 | 2002-07-11 | 序列号18的生物活性肽 |
CNB021410410A Expired - Fee Related CN1213063C (zh) | 2001-07-13 | 2002-07-11 | 序列号12的生物活性肽 |
CN021409811A Expired - Fee Related CN1216072C (zh) | 2001-07-13 | 2002-07-11 | 序列号5的生物活性肽 |
CN02140982XA Expired - Fee Related CN1216073C (zh) | 2001-07-13 | 2002-07-11 | 序列号4的生物活性肽 |
CN021410437A Expired - Fee Related CN1216071C (zh) | 2001-07-13 | 2002-07-11 | 序列号27的生物活性肽 |
CNB021409846A Expired - Fee Related CN1210304C (zh) | 2001-07-13 | 2002-07-11 | 序列号3的生物活性肽 |
CNB021409838A Expired - Fee Related CN100412087C (zh) | 2001-07-13 | 2002-07-11 | 序列号2的生物活性肽 |
CN021409781A Expired - Fee Related CN1216069C (zh) | 2001-07-13 | 2002-07-11 | 序列号25的生物活性肽 |
CN021410399A Expired - Fee Related CN1216068C (zh) | 2001-07-13 | 2002-07-11 | 序列号14的生物活性肽 |
CNB021409854A Expired - Fee Related CN1210298C (zh) | 2001-07-13 | 2002-07-11 | 序列号1的生物活性肽 |
CNB02140979XA Expired - Fee Related CN1213060C (zh) | 2001-07-13 | 2002-07-11 | 序列号10的生物活性肽 |
CNB021409722A Expired - Fee Related CN1213065C (zh) | 2001-07-13 | 2002-07-11 | 序列号7的生物活性肽 |
CNB021409692A Expired - Fee Related CN1210293C (zh) | 2001-07-13 | 2002-07-11 | 序列号23的生物活性肽 |
CNB021409773A Expired - Fee Related CN1213067C (zh) | 2001-07-13 | 2002-07-11 | 序列号9的生物活性肽 |
CNB021410445A Expired - Fee Related CN1223603C (zh) | 2001-07-13 | 2002-07-11 | 序列号26的生物活性肽 |
CNB021410380A Expired - Fee Related CN1215081C (zh) | 2001-07-13 | 2002-07-11 | 序列号16的生物活性肽 |
CNB021410364A Expired - Fee Related CN1210300C (zh) | 2001-07-13 | 2002-07-11 | 序列号29的生物活性肽 |
CNB021409706A Expired - Fee Related CN1210294C (zh) | 2001-07-13 | 2002-07-11 | 序列号21的生物活性肽 |
CNB021410429A Expired - Fee Related CN1213064C (zh) | 2001-07-13 | 2002-07-11 | 序列号28的生物活性肽 |
CN021409757A Expired - Fee Related CN1216067C (zh) | 2001-07-13 | 2002-07-11 | 序列号15的生物活性肽 |
CNB021409749A Expired - Fee Related CN1210297C (zh) | 2001-07-13 | 2002-07-11 | 序列号17的生物活性肽 |
CNB021409684A Expired - Fee Related CN1210292C (zh) | 2001-07-13 | 2002-07-11 | 序列号22的生物活性肽 |
CNB021410356A Expired - Fee Related CN1223602C (zh) | 2001-07-13 | 2002-07-11 | 序列号11的生物活性肽 |
CNB021409803A Expired - Fee Related CN1213061C (zh) | 2001-07-13 | 2002-07-11 | 序列号6的生物活性肽 |
CNB021409730A Expired - Fee Related CN1210295C (zh) | 2001-07-13 | 2002-07-11 | 序列号24的生物活性肽 |
CNB021409765A Expired - Fee Related CN1213066C (zh) | 2001-07-13 | 2002-07-11 | 序列号8的生物活性肽 |
Family Applications Before (22)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021410402A Expired - Fee Related CN1213062C (zh) | 2001-07-13 | 2002-07-11 | 序列号13的生物活性肽 |
CN021409862A Expired - Fee Related CN1216070C (zh) | 2001-07-13 | 2002-07-11 | 序列号20的生物活性肽 |
CNB021409870A Expired - Fee Related CN1210299C (zh) | 2001-07-13 | 2002-07-11 | 序列号19的生物活性肽 |
CNB021409714A Expired - Fee Related CN1210296C (zh) | 2001-07-13 | 2002-07-11 | 序列号30的生物活性肽 |
CNB021410372A Expired - Fee Related CN1210301C (zh) | 2001-07-13 | 2002-07-11 | 序列号18的生物活性肽 |
CNB021410410A Expired - Fee Related CN1213063C (zh) | 2001-07-13 | 2002-07-11 | 序列号12的生物活性肽 |
CN021409811A Expired - Fee Related CN1216072C (zh) | 2001-07-13 | 2002-07-11 | 序列号5的生物活性肽 |
CN02140982XA Expired - Fee Related CN1216073C (zh) | 2001-07-13 | 2002-07-11 | 序列号4的生物活性肽 |
CN021410437A Expired - Fee Related CN1216071C (zh) | 2001-07-13 | 2002-07-11 | 序列号27的生物活性肽 |
CNB021409846A Expired - Fee Related CN1210304C (zh) | 2001-07-13 | 2002-07-11 | 序列号3的生物活性肽 |
CNB021409838A Expired - Fee Related CN100412087C (zh) | 2001-07-13 | 2002-07-11 | 序列号2的生物活性肽 |
CN021409781A Expired - Fee Related CN1216069C (zh) | 2001-07-13 | 2002-07-11 | 序列号25的生物活性肽 |
CN021410399A Expired - Fee Related CN1216068C (zh) | 2001-07-13 | 2002-07-11 | 序列号14的生物活性肽 |
CNB021409854A Expired - Fee Related CN1210298C (zh) | 2001-07-13 | 2002-07-11 | 序列号1的生物活性肽 |
CNB02140979XA Expired - Fee Related CN1213060C (zh) | 2001-07-13 | 2002-07-11 | 序列号10的生物活性肽 |
CNB021409722A Expired - Fee Related CN1213065C (zh) | 2001-07-13 | 2002-07-11 | 序列号7的生物活性肽 |
CNB021409692A Expired - Fee Related CN1210293C (zh) | 2001-07-13 | 2002-07-11 | 序列号23的生物活性肽 |
CNB021409773A Expired - Fee Related CN1213067C (zh) | 2001-07-13 | 2002-07-11 | 序列号9的生物活性肽 |
CNB021410445A Expired - Fee Related CN1223603C (zh) | 2001-07-13 | 2002-07-11 | 序列号26的生物活性肽 |
CNB021410380A Expired - Fee Related CN1215081C (zh) | 2001-07-13 | 2002-07-11 | 序列号16的生物活性肽 |
CNB021410364A Expired - Fee Related CN1210300C (zh) | 2001-07-13 | 2002-07-11 | 序列号29的生物活性肽 |
CNB021409706A Expired - Fee Related CN1210294C (zh) | 2001-07-13 | 2002-07-11 | 序列号21的生物活性肽 |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN021409757A Expired - Fee Related CN1216067C (zh) | 2001-07-13 | 2002-07-11 | 序列号15的生物活性肽 |
CNB021409749A Expired - Fee Related CN1210297C (zh) | 2001-07-13 | 2002-07-11 | 序列号17的生物活性肽 |
CNB021409684A Expired - Fee Related CN1210292C (zh) | 2001-07-13 | 2002-07-11 | 序列号22的生物活性肽 |
CNB021410356A Expired - Fee Related CN1223602C (zh) | 2001-07-13 | 2002-07-11 | 序列号11的生物活性肽 |
CNB021409803A Expired - Fee Related CN1213061C (zh) | 2001-07-13 | 2002-07-11 | 序列号6的生物活性肽 |
CNB021409730A Expired - Fee Related CN1210295C (zh) | 2001-07-13 | 2002-07-11 | 序列号24的生物活性肽 |
CNB021409765A Expired - Fee Related CN1213066C (zh) | 2001-07-13 | 2002-07-11 | 序列号8的生物活性肽 |
Country Status (2)
Country | Link |
---|---|
US (6) | US7491689B2 (zh) |
CN (30) | CN1213062C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI353252B (en) | 2004-04-28 | 2011-12-01 | Cms Peptides Patent Holding Company Ltd | Biologically active peptide vapeehptllteaplnpk der |
CN1799623B (zh) * | 2005-01-05 | 2011-01-26 | 康哲医药研究(深圳)有限公司 | 生物活性肽在制备用于防治关节炎的药物中的用途 |
RU2423375C2 (ru) | 2005-07-26 | 2011-07-10 | СиЭмЭс ПЕПТАЙДЗ ПЭЙТЕНТ ХОЛДИНГ КОМПАНИ ЛИМИТЕД | Новые биологически активные пептиды и их новое применение |
CN105254708B (zh) * | 2015-11-24 | 2019-03-12 | 福州大学 | 一种胡萝卜籽抗氧化三肽及其制备方法与应用 |
WO2019161487A1 (en) * | 2018-02-20 | 2019-08-29 | University Of Manitoba | Food protein-derived peptides as bitter taste blockers |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1142571A (en) | 1966-02-22 | 1969-02-12 | Walter Friedrich Wilhelm Kuhlm | A new polypeptide, and a method of preparing it |
US3992364A (en) | 1966-02-22 | 1976-11-16 | Walter Kuhlmey | Physiologically active polypeptide preparation |
EP0585957A1 (en) | 1986-08-06 | 1994-03-09 | Ajinomoto Co., Inc. | Recombinant B-cell differentiation factor |
US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
DE3827490A1 (de) | 1988-08-12 | 1990-02-15 | Hor Fer Vit Pharma Gmbh | Herrichtung und verwendung eines physiologisch aktiven polypeptids zur aids-therapie |
EP0382012B1 (en) | 1989-01-25 | 1995-05-17 | Commonwealth Scientific And Industrial Research Organisation | Polypeptides, antigens or vaccines protective against babesiosis |
US5242821A (en) | 1989-07-10 | 1993-09-07 | Valio, Finnish Co-Operative Dairies' Association | Lactococcus promoter and signal sequences for expression in bacteria |
US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
AU7142391A (en) | 1989-12-22 | 1991-07-24 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Synthetic peptides as modulators of functional responses of intact cells |
WO1992009300A1 (en) * | 1990-11-21 | 1992-06-11 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
DE4122585C2 (de) | 1991-07-08 | 1994-11-03 | Horfervit Pharma Gmbh | Verwendung einer Peptidfraktion bei Stoffwechselstörungen mit Gewichtsverlust |
US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
US5556744A (en) * | 1992-05-29 | 1996-09-17 | The Trustees Of The University Of Pennsylvania | Methods and compositions for diagnosing and treating certain HIV infected patients |
ATE253635T1 (de) | 1993-06-15 | 2003-11-15 | Du Pont | Rekombinante spinnerseide analoge |
US5519114A (en) | 1993-10-29 | 1996-05-21 | University Of Florida Research Foundation, Inc. | Retroviral superantigens, superantigen peptides, and methods of use |
US6013628A (en) * | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
US5760000A (en) * | 1994-05-13 | 1998-06-02 | University Technologies International,Inc. | Inhibition of liver cancer by the use of GnRH and GnRH analogs |
WO1995035389A1 (en) | 1994-06-17 | 1995-12-28 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method for introduction of genetic material into microorganisms and transformants obtained therewith |
US5958416A (en) | 1994-12-16 | 1999-09-28 | Regents Of The University Of Minnesota | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease |
US5874405A (en) | 1994-12-16 | 1999-02-23 | Birnbaum; Gary | Heat shock protein peptides that share sequences with cyclic nucleotide phosphodiesterase and methods for modulating autoimmune central nervous system disease |
IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
GB9606016D0 (en) | 1996-03-22 | 1996-05-22 | Smithkline Beecham Plc | Novel use |
US5861483A (en) | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
SE9603468D0 (sv) | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
DE19700535C1 (de) | 1997-01-10 | 1998-07-02 | Horfervit Pharma Gmbh | Verwendung eines physiologisch aktiven Polypeptids |
WO1998054339A1 (en) | 1997-05-27 | 1998-12-03 | Hanil Synthetic Fiber Co., Ltd. | PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE) |
EP1012157A1 (en) | 1997-06-20 | 2000-06-28 | Human Genome Sciences, Inc. | $i(BORRELIA BURGDORFERI) POLYNUCLEOTIDES AND SEQUENCES |
IL121191A0 (en) | 1997-06-29 | 1997-11-20 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
KR19990024297A (ko) | 1997-08-07 | 1999-04-06 | 오종석 | 인체 구강내 치태형성을 억제하는 신규한 유산균 |
US6036652A (en) * | 1998-05-12 | 2000-03-14 | Colin Corporation | Blood pressure estimating apparatus and method |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
WO2000012762A1 (en) | 1998-09-01 | 2000-03-09 | Millennium Pharmaceuticals, Inc. | A novel protein related to melanoma-inhibiting protein and uses thereof |
US6413530B1 (en) | 1999-04-21 | 2002-07-02 | University Of Florida Research Foundation, Inc. | Pesticidal peptides |
FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
AU7899100A (en) | 1999-10-18 | 2001-04-30 | Shanghai Bio Road Gene Development Ltd. | A novel polypeptide, a human casein kinase 48 and the polynucleotide encoding the polypeptide |
EP1478659B1 (en) | 2001-07-13 | 2008-11-12 | CMS Peptides Patent Holding Company Limited | Biologically active peptides |
US20040043438A1 (en) * | 2002-05-16 | 2004-03-04 | Alk-Abello A/S | Allergen mutants |
-
2002
- 2002-07-11 CN CNB021410402A patent/CN1213062C/zh not_active Expired - Fee Related
- 2002-07-11 CN CN021409862A patent/CN1216070C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409870A patent/CN1210299C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409714A patent/CN1210296C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021410372A patent/CN1210301C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021410410A patent/CN1213063C/zh not_active Expired - Fee Related
- 2002-07-11 CN CN021409811A patent/CN1216072C/zh not_active Expired - Fee Related
- 2002-07-11 CN CN02140982XA patent/CN1216073C/zh not_active Expired - Fee Related
- 2002-07-11 CN CN021410437A patent/CN1216071C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409846A patent/CN1210304C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409838A patent/CN100412087C/zh not_active Expired - Fee Related
- 2002-07-11 CN CN021409781A patent/CN1216069C/zh not_active Expired - Fee Related
- 2002-07-11 CN CN021410399A patent/CN1216068C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409854A patent/CN1210298C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB02140979XA patent/CN1213060C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409722A patent/CN1213065C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409692A patent/CN1210293C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409773A patent/CN1213067C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021410445A patent/CN1223603C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021410380A patent/CN1215081C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021410364A patent/CN1210300C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409706A patent/CN1210294C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021410429A patent/CN1213064C/zh not_active Expired - Fee Related
- 2002-07-11 CN CN021409757A patent/CN1216067C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409749A patent/CN1210297C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409684A patent/CN1210292C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021410356A patent/CN1223602C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409803A patent/CN1213061C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409730A patent/CN1210295C/zh not_active Expired - Fee Related
- 2002-07-11 CN CNB021409765A patent/CN1213066C/zh not_active Expired - Fee Related
- 2002-09-05 US US10/237,405 patent/US7491689B2/en not_active Expired - Lifetime
-
2006
- 2006-06-16 US US11/455,289 patent/US7402653B2/en not_active Expired - Fee Related
- 2006-07-18 US US11/458,113 patent/US7718768B2/en not_active Expired - Fee Related
- 2006-07-31 US US11/460,998 patent/US7696152B2/en not_active Expired - Fee Related
-
2007
- 2007-05-22 US US11/751,636 patent/US20070232522A1/en not_active Abandoned
-
2008
- 2008-03-17 US US12/049,382 patent/US20080293641A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1213064C (zh) | 序列号28的生物活性肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: YITAI MEDICINE RESEARCH (SHENZHEN) CO., LTD. Free format text: FORMER OWNER: KANGZHE PHARMACEUTICAL INDUSTRY CO., LTD., SHENZHEN Effective date: 20030812 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030812 Address after: 518029, Guangdong, Shenzhen Futian District Bagua three road deep medicine building, room 301-304 Applicant after: Yitai Medicine Research (Shenzhen) Co., Ltd. Address before: 518029, Guangdong, Shenzhen, Futian District Bagua three road deep medicine building on the eastern side of the two floor Applicant before: Kangzhe Pharmaceutical Industry Co., Ltd., Shenzhen |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: KANGZHE MEDICINE RESEARCH ( SHENZHEN ) CO., LTD. Free format text: FORMER NAME OR ADDRESS: YITAI MEDICINE RESEARCH (SHENZHEN) CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 518000. A biological incubator building in central high tech Zone, Guangdong, Shenzhen province 2-413 Patentee after: Pepharm R. & D. Ltd. Address before: 518029, Guangdong, Shenzhen Futian District Bagua three road deep medicine building, room 301-304 Patentee before: Yitai Medicine Research (Shenzhen) Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050803 Termination date: 20210711 |